Nxstage Medical (NXTM) Reports In-Line Q4 EPS; Issues Light FY16 Revenue Outlook

Nxstage Medical (NASDAQ: NXTM) reported Q4 EPS of ($0.04), in-line with the analyst estimate of ($0.04). Revenue for the quarter came in at $89.8 million versus the consensus estimate of $86.83 million.

GUIDANCE:

Nxstage Medical sees Q1 2016 revenue of $87-89 million, versus the consensus of $89.3 million.

Nxstage Medical sees FY2016 revenue of $355-360 million, versus the consensus of $371.0 million.

For earnings history and earnings-related data on Nxstage Medical (NXTM) click here.

You May Also Be Interested In

• ATN International (ATNI) Misses Q1 EPS by 46c ; Offers Guidance
• SLM (SLM) Tops Q1 EPS by 20c; offers guidance
• Nanometrics (NANO) Issues Business Update, Reports FY23 Results